Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three years.
Findings from the ADjoin long-term extension study will be presented at the American Academy of Dermatology Annual Meeting from March 7-11 in Orlando.
Among patients receiving a once-monthly maintenance dose, 50 percent achieved complete skin clearance, while 87 percent maintained almost-clear skin at three years. Most patients did not require additional topical treatments. Ebglyss, an interleukin-13 inhibitor, continues to show a consistent safety profile with no new safety concerns, the company said.
LLY is currently trading at $905.91 down 0.75 percent or $6.85 on the New York Stock Exchange.
For comments and feedback: editorial@rttnews.com